CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness

Last updated: March 17, 2016
Project Number: RC0756-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


1.  What is the clinical efficacy and safety of olopatadine for the treatment of allergic conjunctivitis?

2.  What is the cost-effectiveness of olopatadine for the treatment of allergic conjunctivitis?

Key Message

Pooled estimates from four studies included in a systematic review showed that there was some evidence that olopatadine may be more effective than ketotifen in improving ocular itching, but not tearing, after 14 days of treatment. Data from one recent RCT showed that there was a similar reduction in the composite score (itching, tearing, and conjunctival hyperemia) with olopatadine or ketotifen after 28 days of treatment. Both drugs were found safe in the systematic review and the RCT. There were no studies identified comparing olopatadine to cromolyn, and no cost-effectiveness analyses of olopatadine for the treatment of allergic conjunctivitis were found.